Chilean President Boric Meets with SINOVAC Chairman and CEO Weidong Yin

On December 12, 2023, Chilean President Gabriel Boric met with a delegation led by Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC, at the Presidential Palace La Moneda in Chile. Both sides have reached a consensus on local vaccine production and collaborative research and development of health products.

President Boric firstly mentioned about his recent successful visit to China. He emphasized that during his meeting with Chinese President Xi Jinping, both leaders jointly affirmed the need to further deepen cooperation in the health care among the numerous collaborations between China and Chile. He also stated that the Chilean government has established strategic goals for the development of vaccine research and industrialization in Chile.

Yin Weidong responded, "Mr. President’s visit to China was indeed very successful. Your charisma attracted many Chinese people and won praise. The purpose of our SINOVAC delegation's special visit to Chile is to better implement the consensus reached by the top leaders of both countries. We are exploring how to accelerate collaborative projects in vaccine research and industrialization between China and Chile." Developing vaccine's research and development and localization projects in Chile is the company's long-term strategy, and SINOVAC will firmly approach this goal which is highly consistent with the strategic direction of the Chilean government.

Yin Weidong stated that both sides have set up a special working group Studying Chile's successful anti-epidemic experience during the COVID-19 epidemic. It aims to maximize Chile's research strengths in bio-pharmaceutics and leverage SINOVAC's expertise in vaccine research and localization.

The goal is to face the pandemic challenge more efficiently, to enhance vaccine's accessibility and affordability, and to contribute to the health and well-being of the people in Chile and other countries in South America.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.